Nivolumab for Cutaneous Melanoma
Study Summary
This trial is studying nivolumab and ipilimumab to see how well they work with or without sargramostim in treating patients with stage III-IV melanoma that cannot be removed by surgery.
- Cutaneous Melanoma
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Awards & Highlights
Trial Design
Find a site
Who is running the clinical trial?
Frequently Asked Questions
What are some of the most well-known applications for Nivolumab?
"Nivolumab is most often given to patients with cancer, but it can also be used to help people undergoing allogenic bone marrow transplantation therapy, those with unresectable melanoma, and squamous cell carcinoma."
How many study participants are receiving care in this trial?
"This clinical trial needs 600 willing and eligible participants. Those who fit the inclusion criteria can enroll at Cancer and Blood Specialists-Henderson in Henderson, Nevada or IHA Hematology Oncology Consultants-Canton in Canton, Michigan."
What is the data telling us about Nivolumab's effectiveness?
"Nivolumab was first studied in 2001 at the Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium. As of now, there have been 508 completed trials with 832 more currently underway across the globe; many in Henderson, Nevada."